US court blocks EPA order to eliminate PFAS in plastic containers

Legal basis of the ruling (TSCA, “new use” vs existing use)

• Core issue: EPA used the Toxic Substances Control Act (TSCA) “significant new use” (Section 5) authority to stop Inhance’s decades‑old fluorination process.
• Many commenters argue this was procedurally wrong: Section 5 is for new uses; longstanding uses must be regulated under Section 6, which requires a fuller cost–benefit analysis.
• Others counter that this is legalistic hair‑splitting that undermines health protection when new science shows existing uses are dangerous.

Interpretation of “new use” and EPA consistency

• Court and critics note EPA itself previously defined “new use” for PFAS as uses not ongoing by the end of 2015, which would exempt Inhance’s process.
• Supporters of the EPA view say courts are stretching language and even elevating non‑binding FAQs over formal rules.
• Dispute over whether the ruling reflects proper adherence to statute or “judicial activism” hostile to regulation.

Role and behavior of the courts (especially the 5th Circuit)

• Some see the decision as a correct check on an agency overstepping legal bounds, protecting rule of law and due process.
• Others see the 5th Circuit as ideologically driven, frequently reversed, and deliberately sabotaging regulatory agencies.
• Debate over whether courts should leave harmful rules in place temporarily while agencies fix technical defects.

Congress, Chevron, and systemic dysfunction

• Several note Congress already “did its job” by creating EPA and TSCA, but also intentionally made it harder to ban existing uses than new ones.
• Others argue Congress is currently gridlocked and structurally unable to update laws; this forces EPA to “shoehorn” old statutes onto new problems.
• Concern that weakening Chevron deference would further limit agencies’ ability to act on scientific expertise.

PFAS risk, technical nuances, and Inhance’s process

• Broad agreement that PFAS are dangerous in many contexts; some point out not all PFAS are equal and many drugs contain PFAS structures.
• Inhance claims to have cut PFAS by >90%, with only trace formation compared to overall PFAS production; commenters are divided on whether that makes the risk negligible or still unacceptable.
• Unclear to commenters exactly how much leaching occurs and how to weigh that against industrial benefits.

Public trust and personal responses

• Some express deep pessimism about U.S. regulation and politics, even considering emigration.
• Others stress individual vigilance: researching products, relying on online communities, but note these can slide into conspiracism and poor epistemics.